Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Disaggregation Of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net Revenue	$ 16,672,416	$ 14,626,904	$ 46,534,358	$ 42,462,265
United States [Member]
Net Revenue	13,713,000		40,050,000
Rest Of World [Member]
Net Revenue	2,959,000		6,484,000
Concentrate Products [Member]
Net Revenue	16,604,000		46,329,000
Concentrate Products [Member] | United States [Member]
Net Revenue	13,713,000		40,050,000
Concentrate Products [Member] | Rest Of World [Member]
Net Revenue	2,891,000		6,279,000
License Fee [Member]
Net Revenue		556,000		1,655,000
License Fee [Member] | Drug Revenue [Member]
Net Revenue	68,000		205,000
License Fee [Member] | Drug Revenue [Member] | Rest Of World [Member]
Net Revenue	68,000		205,000
License Fee [Member] | Concentrate Products [Member]
Net Revenue	505,000		1,514,000
License Fee [Member] | Concentrate Products [Member] | United States [Member]
Net Revenue	505,000		1,514,000
Product Sales [Member]
Net Revenue		$ 14,061,000		$ 40,807,000
Product Sales [Member] | Concentrate Products [Member]
Net Revenue	16,099,000		44,815,000
Product Sales [Member] | Concentrate Products [Member] | United States [Member]
Net Revenue	13,208,000		38,536,000
Product Sales [Member] | Concentrate Products [Member] | Rest Of World [Member]
Net Revenue	$ 2,891,000		$ 6,279,000